Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
197.55
+1.18 (+0.60%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
AbbVie Stock Price Forecast: $200 On The Cards?
June 20, 2024
Strategic partnerships and acquisitions enhance AbbVie's pipeline.
Via
Talk Markets
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
June 20, 2024
Via
Benzinga
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
June 20, 2024
Discover top retirement stocks with strong buy ratings, offering reliable growth and income to ensure a comfortable retirement.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
June 20, 2024
The power of compounding can build huge amounts of passive income.
Via
The Motley Fool
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
June 20, 2024
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries.
Via
InvestorPlace
Earn Income While Playing The Hottest Sectors
June 19, 2024
Via
Talk Markets
Looking Into AbbVie's Recent Short Interest
June 13, 2024
Via
Benzinga
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
June 11, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today
June 10, 2024
Via
Benzinga
3 High-Dividend Stocks to Buy and Hold Forever: June 2024 Edition
June 20, 2024
Looking for high-yield dividend stocks to buy and hold? Take a look at these three buy-rated Dividend Aristocrats.
Via
InvestorPlace
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
June 19, 2024
Don't sleep on the value of quality dividends.
Via
The Motley Fool
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
June 18, 2024
Via
Benzinga
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
June 17, 2024
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having...
Via
Benzinga
2 Dividend Stocks That Could Pay You for Life
June 16, 2024
There are other reasons to love these businesses, too.
Via
The Motley Fool
Analyst Scoreboard: 6 Ratings For AbbVie
June 05, 2024
Via
Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks
June 14, 2024
Are you looking for some defenders for your portfolio? Here are three dividend stocks to protect and grow your wealth.
Via
InvestorPlace
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
June 12, 2024
Thanks to the predictability of big businesses, the bargains found among undervalued blue-chip stocks are simply more trustworthy.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
June 11, 2024
Via
Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 07, 2024
Via
Benzinga
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
June 07, 2024
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance...
Via
Benzinga
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'
June 07, 2024
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners.
Via
Benzinga
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
June 06, 2024
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.
Via
Benzinga
7 Stocks That Could Safely 10X by 2030
June 06, 2024
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align.
Via
InvestorPlace
Hedge Fund Favorites: 7 Stocks to Buy When You’re Feeling Jittery
June 06, 2024
With the hedge funds targeting certain ideas with their vast resources, retail investors can ride coattails with these stocks to buy.
Via
InvestorPlace
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
June 05, 2024
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off.
Via
InvestorPlace
2 High-Yield Dividend Stocks to Buy Right Now
June 05, 2024
These two high-yield dividend stocks are top buys right now.
Via
The Motley Fool
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
June 05, 2024
Top dividend stocks across various sectors continue to reward investors, even as they face sales shortfalls and leadership changes.
Via
InvestorPlace
Top Stocks to Buy in June
June 04, 2024
Here are a few high-quality stocks trading at intriguing valuations.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.